Recent Investment Analysts’ Ratings Changes for Intuitive Surgical (ISRG)

Several analysts have recently updated their ratings and price targets for Intuitive Surgical (NASDAQ: ISRG):

  • 2/10/2018 – Intuitive Surgical was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 2/8/2018 – Intuitive Surgical was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $443.17 price target on the stock.
  • 2/6/2018 – Intuitive Surgical had its price target lowered by analysts at Citigroup Inc to $507.00. They now have a “buy” rating on the stock.
  • 1/26/2018 – Intuitive Surgical had its price target raised by analysts at Morgan Stanley from $450.00 to $500.00. They now have an “overweight” rating on the stock.
  • 1/26/2018 – Intuitive Surgical was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Intuitive Surgical exited the fourth quarter on a solid note, beating the Zacks Consensus Estimate on both the counts. The company outperformed in the Mature and Growth procedures, especially in general and thoracic surgery. Procedure performance in Asia showed continued strength with solid growth in China, Japan and Korea. A positive outlook for the coming quarters also raises our confidence. Further, incremental spending on product development and higher investments in international markets are likely to drive long-term growth. Over the last three months, Intuitive Surgical has been trading above the broader industry. However, a surge in operating expenses and the reinstatement of the medical device tax are likely to dampen the company’s bottom line in the days to come. Further, the da Vinci Surgical System has a long sale and purchase order cycle. Added to this, cutthroat competition in the niche space is a concern.”
  • 1/26/2018 – Intuitive Surgical had its price target raised by analysts at Royal Bank of Canada to $430.00. They now have a “sector perform” rating on the stock.
  • 1/26/2018 – Intuitive Surgical had its “hold” rating reaffirmed by analysts at Canaccord Genuity. They now have a $410.00 price target on the stock, up previously from $380.00. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 1/26/2018 – Intuitive Surgical had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $490.00 price target on the stock. They wrote, “Top-line results in-line with prelim results; EPS beat. ISRG reported 4Q top-line results consistent with its pre-announcement, including revenue of $892MM (+18%), and procedure growth of 16%. Adj. 4Q EPS was $2.54, beating FactSet consensus by $0.30 on higher-than-expected revenue, better- than-expected margins and a lower tax rate.””
  • 1/26/2018 – Intuitive Surgical had its “buy” rating reaffirmed by analysts at Citigroup Inc. They now have a $531.00 price target on the stock.
  • 1/26/2018 – Intuitive Surgical had its price target raised by analysts at Barclays PLC to $475.00. They now have an “overweight” rating on the stock. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 1/26/2018 – Intuitive Surgical had its “hold” rating reaffirmed by analysts at Piper Jaffray Companies.
  • 1/25/2018 – Intuitive Surgical had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $480.00 price target on the stock, up previously from $400.00.
  • 1/18/2018 – Intuitive Surgical had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $475.00 price target on the stock, up previously from $390.00.
  • 1/11/2018 – Intuitive Surgical was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 1/11/2018 – Intuitive Surgical had its “overweight” rating reaffirmed by analysts at Barclays PLC. They now have a $465.00 price target on the stock.
  • 1/8/2018 – Intuitive Surgical was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $434.75 price target on the stock.
  • 1/5/2018 – Intuitive Surgical had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $410.00 price target on the stock. They wrote, “ISRG announced preliminary 4Q revenue of $892MM (+18%), beating FactSet consensus by $45MM. The beat was driven by 20% y/y growth in system revenue and 18% y/y growth in instrument and accessory revenue.””
  • 1/3/2018 – Intuitive Surgical was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $409.00 price target on the stock. According to Zacks, “Over the last three months, Intuitive Surgical has been consistently trading above the broader industry. Procedure performance in Asia showed continued strength with solid growth in China, Japan and Korea. Moreover, the company gained significantly on regulatory approvals and favorable study results for da Vinci X robotic platform. A positive outlook for the coming quarters also raises our confidence in the stock. However, unfavorable foreign exchange movements are impacting the company’s results. Intuitive Surgical expects margins to fluctuate based on the company’s mix of new products, mix of systems in instrument and accessory revenue segments, and the reinstatement of the medical device tax in 2018. The company’s da Vinci Surgical System has a long sale and purchase order cycle which might act against the company’s growth.”
  • 1/3/2018 – Intuitive Surgical is now covered by analysts at Evercore ISI. They set an “in-line” rating and a $380.00 price target on the stock.
  • 12/29/2017 – Intuitive Surgical was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 12/20/2017 – Intuitive Surgical was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Over the last three months, Intuitive Surgical has been consistently trading above the broader industry. Procedure performance in Asia showed continued strength with solid growth in China, Japan and Korea. Moreover, the company gained significantly on the CE Mark approval for da Vinci X in Europe. The stock has got a further boost on the FDA approval of the same in the recent past. A positive outlook for the coming quarters also raises our confidence in the stock. However, unfavorable foreign exchange movements are impacting the company’s results. Intuitive Surgical expects margins to fluctuate based on the company’s mix of new products, mix of systems in instrument and accessory revenue segments, and the reinstatement of the medical device tax in 2018. The company’s da Vinci Surgical System has a long sale and purchase order cycle which might act against the company’s growth.”

Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) opened at $392.91 on Monday. Intuitive Surgical, Inc. has a 12-month low of $233.66 and a 12-month high of $452.00. The firm has a market capitalization of $44,123.20, a P/E ratio of 69.17, a price-to-earnings-growth ratio of 4.63 and a beta of 0.50.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, January 25th. The medical equipment provider reported $2.54 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.27 by $0.27. Intuitive Surgical had a return on equity of 19.93% and a net margin of 21.09%. The firm had revenue of $892.40 million during the quarter, compared to the consensus estimate of $866.54 million. During the same quarter in the previous year, the company posted $2.03 earnings per share. The business’s revenue was up 17.9% on a year-over-year basis. equities analysts expect that Intuitive Surgical, Inc. will post 7.93 earnings per share for the current fiscal year.

In other Intuitive Surgical news, CEO Gary S. Guthart sold 28,525 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $414.50, for a total value of $11,823,612.50. Following the completion of the sale, the chief executive officer now owns 311,469 shares in the company, valued at $129,103,900.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Curet Myriam sold 262 shares of the business’s stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $431.50, for a total value of $113,053.00. Following the completion of the sale, the executive vice president now owns 2,152 shares of the company’s stock, valued at approximately $928,588. The disclosure for this sale can be found here. Insiders sold 85,016 shares of company stock valued at $35,133,026 in the last quarter. Corporate insiders own 2.20% of the company’s stock.

Intuitive Surgical, Inc (Intuitive) designs, manufactures and markets da Vinci Surgical Systems, and related instruments and accessories. The Company’s da Vinci Surgical System consists of a surgeon’s console, a patient-side cart and a vision system. The da Vinci Surgical System translates a surgeon’s hand movements, which are performed on instrument controls at a console, into corresponding micro-movements of instruments positioned inside the patient through small incisions or ports.

Receive News & Ratings for Intuitive Surgical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuitive Surgical Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply